NASDAQ:VIVE - Viveve Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.20 +0.11 (+5.26 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$2.09
Today's Range$2.00 - $2.20
52-Week Range$1.60 - $5.40
Volume79,800 shs
Average Volume348,831 shs
Market Capitalization$67.81 million
P/E Ratio-1.04
Dividend YieldN/A
Beta-0.25
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VIVE
Previous SymbolOTCMKTS:PLCSD
CUSIPN/A
Phone720-696-8100

Debt

Debt-to-Equity Ratio3.42
Current Ratio3.72
Quick Ratio3.20

Price-To-Earnings

Trailing P/E Ratio-1.04
Forward P/E Ratio-1.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.29 million
Price / Sales4.54
Cash FlowN/A
Price / CashN/A
Book Value($0.13) per share
Price / Book-16.92

Profitability

EPS (Most Recent Fiscal Year)($2.11)
Net Income$-36,950,000.00
Net Margins-243.98%
Return on Equity-838.28%
Return on Assets-104.99%

Miscellaneous

Employees103
Outstanding Shares31,540,000
Market Cap$67.81 million
OptionableOptionable

Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How were Viveve Medical's earnings last quarter?

Viveve Medical Inc (NASDAQ:VIVE) posted its earnings results on Friday, November, 9th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.06. The company earned $4.82 million during the quarter, compared to the consensus estimate of $4.60 million. Viveve Medical had a negative return on equity of 838.28% and a negative net margin of 243.98%. View Viveve Medical's Earnings History.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Viveve Medical.

What price target have analysts set for VIVE?

6 equities research analysts have issued 12-month price targets for Viveve Medical's stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Viveve Medical's stock price to reach $8.75 in the next year. This suggests a possible upside of 297.7% from the stock's current price. View Analyst Price Targets for Viveve Medical.

What is the consensus analysts' recommendation for Viveve Medical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viveve Medical.

What are Wall Street analysts saying about Viveve Medical stock?

Here are some recent quotes from research analysts about Viveve Medical stock:
  • 1. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)
  • 2. Maxim Group analysts commented, "4Q17 revenue of $5.1M, up 108% y/y, was inline with the preannouncement." (3/16/2018)

Has Viveve Medical been receiving favorable news coverage?

Headlines about VIVE stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Viveve Medical earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the company's share price in the immediate future.

Who are some of Viveve Medical's key competitors?

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the folowing people:
  • Mr. Scott C. Durbin, CEO, Sec. & Director (Age 49)
  • Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 60)
  • Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 60)
  • Mr. Jim B. Robbins, VP of Fin. & Admin. and Principal Accounting Officer (Age 54)
  • Mr. Martin Kerber, VP of Operations

When did Viveve Medical IPO?

(VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group served as the underwriters for the IPO and Maxim Group was co-manager.

Who are Viveve Medical's major shareholders?

Viveve Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.24%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller and Scott Durbin. View Institutional Ownership Trends for Viveve Medical.

Which major investors are selling Viveve Medical stock?

VIVE stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. View Insider Buying and Selling for Viveve Medical.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $2.20.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $67.81 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.

What is Viveve Medical's official website?

The official website for Viveve Medical is http://www.viveve.com.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]


MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Featured Article: What is systematic risk?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel